Cargando…

Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease

BACKGROUND: Discovery of early-stage biomarkers is a long-sought goal of Alzheimer’s disease (AD) diagnosis. Age is the greatest risk factor for most AD and accumulating evidence suggests that age-dependent elevation of asparaginyl endopeptidase (AEP) in the brain may represent a new biological mark...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shan-Shan, Liu, Zi-Kai, Liu, Jing-Jing, Cheng, Qing, Wang, Yan-Xia, Liu, Yan, Ni, Wen-Wen, Chen, Hong-Zhuan, Song, Mingke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375181/
https://www.ncbi.nlm.nih.gov/pubmed/34412639
http://dx.doi.org/10.1186/s12951-021-00988-0
_version_ 1783740268314361856
author Wang, Shan-Shan
Liu, Zi-Kai
Liu, Jing-Jing
Cheng, Qing
Wang, Yan-Xia
Liu, Yan
Ni, Wen-Wen
Chen, Hong-Zhuan
Song, Mingke
author_facet Wang, Shan-Shan
Liu, Zi-Kai
Liu, Jing-Jing
Cheng, Qing
Wang, Yan-Xia
Liu, Yan
Ni, Wen-Wen
Chen, Hong-Zhuan
Song, Mingke
author_sort Wang, Shan-Shan
collection PubMed
description BACKGROUND: Discovery of early-stage biomarkers is a long-sought goal of Alzheimer’s disease (AD) diagnosis. Age is the greatest risk factor for most AD and accumulating evidence suggests that age-dependent elevation of asparaginyl endopeptidase (AEP) in the brain may represent a new biological marker for predicting AD. However, this speculation remains to be explored with an appropriate assay method because mammalian AEP exists in many organs and the level of AEP in body fluid isn’t proportional to its concentration in brain parenchyma. To this end, we here modified gold nanoparticle (AuNPs) into an AEP-responsive imaging probe and choose transgenic APPswe/PS1dE9 (APP/PS1) mice as an animal model of AD. Our aim is to determine whether imaging of brain AEP can be used to predict AD pathology. RESULTS: This AEP-responsive imaging probe AuNPs-Cy5.5-A&C consisted of two particles, AuNPs-Cy5.5-AK and AuNPs-Cy5.5-CABT, which were respectively modified with Ala–Ala–Asn–Cys–Lys (AK) and 2-cyano-6-aminobenzothiazole (CABT). We showed that AuNPs-Cy5.5-A&C could be selectively activated by AEP to aggregate and emit strong fluorescence. Moreover, AuNPs-Cy5.5-A&C displayed a general applicability in various cell lines and its florescence intensity correlated well with AEP activity in these cells. In the brain of APP/PS1 transgenic mice , AEP activity was increased at an early disease stage of AD that precedes formation of senile plaques and cognitive impairment. Pharmacological inhibition of AEP with δ-secretase inhibitor 11 (10 mg kg(−1), p.o.) reduced production of β-amyloid (Aβ) and ameliorated memory loss. Therefore, elevation of AEP is an early sign of AD onset. Finally, we showed that live animal imaging with this AEP-responsive probe could monitor the up-regulated AEP in the brain of APP/PS1 mice. CONCLUSIONS: The current work provided a proof of concept that assessment of brain AEP activity by in vivo imaging assay is a potential biomarker for early diagnosis of AD. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-00988-0.
format Online
Article
Text
id pubmed-8375181
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83751812021-08-23 Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease Wang, Shan-Shan Liu, Zi-Kai Liu, Jing-Jing Cheng, Qing Wang, Yan-Xia Liu, Yan Ni, Wen-Wen Chen, Hong-Zhuan Song, Mingke J Nanobiotechnology Research BACKGROUND: Discovery of early-stage biomarkers is a long-sought goal of Alzheimer’s disease (AD) diagnosis. Age is the greatest risk factor for most AD and accumulating evidence suggests that age-dependent elevation of asparaginyl endopeptidase (AEP) in the brain may represent a new biological marker for predicting AD. However, this speculation remains to be explored with an appropriate assay method because mammalian AEP exists in many organs and the level of AEP in body fluid isn’t proportional to its concentration in brain parenchyma. To this end, we here modified gold nanoparticle (AuNPs) into an AEP-responsive imaging probe and choose transgenic APPswe/PS1dE9 (APP/PS1) mice as an animal model of AD. Our aim is to determine whether imaging of brain AEP can be used to predict AD pathology. RESULTS: This AEP-responsive imaging probe AuNPs-Cy5.5-A&C consisted of two particles, AuNPs-Cy5.5-AK and AuNPs-Cy5.5-CABT, which were respectively modified with Ala–Ala–Asn–Cys–Lys (AK) and 2-cyano-6-aminobenzothiazole (CABT). We showed that AuNPs-Cy5.5-A&C could be selectively activated by AEP to aggregate and emit strong fluorescence. Moreover, AuNPs-Cy5.5-A&C displayed a general applicability in various cell lines and its florescence intensity correlated well with AEP activity in these cells. In the brain of APP/PS1 transgenic mice , AEP activity was increased at an early disease stage of AD that precedes formation of senile plaques and cognitive impairment. Pharmacological inhibition of AEP with δ-secretase inhibitor 11 (10 mg kg(−1), p.o.) reduced production of β-amyloid (Aβ) and ameliorated memory loss. Therefore, elevation of AEP is an early sign of AD onset. Finally, we showed that live animal imaging with this AEP-responsive probe could monitor the up-regulated AEP in the brain of APP/PS1 mice. CONCLUSIONS: The current work provided a proof of concept that assessment of brain AEP activity by in vivo imaging assay is a potential biomarker for early diagnosis of AD. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-00988-0. BioMed Central 2021-08-19 /pmc/articles/PMC8375181/ /pubmed/34412639 http://dx.doi.org/10.1186/s12951-021-00988-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Shan-Shan
Liu, Zi-Kai
Liu, Jing-Jing
Cheng, Qing
Wang, Yan-Xia
Liu, Yan
Ni, Wen-Wen
Chen, Hong-Zhuan
Song, Mingke
Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease
title Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease
title_full Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease
title_fullStr Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease
title_full_unstemmed Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease
title_short Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease
title_sort imaging asparaginyl endopeptidase (aep) in the live brain as a biomarker for alzheimer’s disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375181/
https://www.ncbi.nlm.nih.gov/pubmed/34412639
http://dx.doi.org/10.1186/s12951-021-00988-0
work_keys_str_mv AT wangshanshan imagingasparaginylendopeptidaseaepinthelivebrainasabiomarkerforalzheimersdisease
AT liuzikai imagingasparaginylendopeptidaseaepinthelivebrainasabiomarkerforalzheimersdisease
AT liujingjing imagingasparaginylendopeptidaseaepinthelivebrainasabiomarkerforalzheimersdisease
AT chengqing imagingasparaginylendopeptidaseaepinthelivebrainasabiomarkerforalzheimersdisease
AT wangyanxia imagingasparaginylendopeptidaseaepinthelivebrainasabiomarkerforalzheimersdisease
AT liuyan imagingasparaginylendopeptidaseaepinthelivebrainasabiomarkerforalzheimersdisease
AT niwenwen imagingasparaginylendopeptidaseaepinthelivebrainasabiomarkerforalzheimersdisease
AT chenhongzhuan imagingasparaginylendopeptidaseaepinthelivebrainasabiomarkerforalzheimersdisease
AT songmingke imagingasparaginylendopeptidaseaepinthelivebrainasabiomarkerforalzheimersdisease